Article
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator.
European heart journal - 21 Aug 2022
Protonotarios Alexandros, Bariani Riccardo, Cappelletto Chiara, Pavlou Menelaos, García-García Alba, Cipriani Alberto, Protonotarios Ioannis, Rivas Adrian, Wittenberg Regitze, Graziosi Maddalena, Xylouri Zafeirenia, Larrañaga-Moreira José M, de Luca Antonio, Celeghin Rudy, Pilichou Kalliopi, Bakalakos Athanasios, Lopes Luis Rocha, Savvatis Konstantinos, Stolfo Davide, Dal Ferro Matteo, Merlo Marco, Basso Cristina, Freire Javier Limeres, Rodriguez-Palomares Jose F, Kubo Toru, Ripoll-Vera Tomas, Barriales-Villa Roberto, Antoniades Loizos, Mogensen Jens, Garcia-Pavia Pablo, Wahbi Karim, Biagini Elena, Anastasakis Aris, Tsatsopoulou Adalena, Zorio Esther, Gimeno Juan R, Garcia-Pinilla Jose Manuel, Syrris Petros, Sinagra Gianfranco, Bauce Barbara, Elliott Perry M
Abstract excerpt
AIMS: To study the impact of genotype on the performance of the 2019 risk model for arrhythmogenic right ventricular cardiomyopathy (ARVC). METHODS AND RESULTS: The study cohort comprised 554 patients with a definite diagnosis of ARVC and no history of sustained ventricular arrhythmia (VA). During a median follow-up of 6.0 (3.1,12.5) years, 100 patients (18%) experienced the primary VA outcome (sustained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.